Male diabetic sexual impotence: effects of dopaminergic agents.
A double blind study was carried out with placebo and dopaminergic agents in 100 patients with male diabetic sexual impotence. In basal conditions, mean serum FSH, LH, PRL, and T levels did not significantly differ from those found in a normal control group. No significant variations with the exception of PRL reduction were observed after use of the dopaminergic agents. Sexual activity was improved in 50% of cases after 3-4 dihidroxifenilalanine and 10% of those of the placebo group. In patients with bromocriptine, 20% improved their sexual function without changes in those receiving placebo.
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D001971:Bromocriptine; D013739:Testosterone; D004295:Dihydroxyphenylalanine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone